Matt Tremblay - Information
Matt Tremblay currently works as the Vice President, COO and Secretary to the Board of Directors of Business Development for The Scripps Research Institute. At the same time, he serves as the CEO of California Institute for Biomedical Research. A full profile of Matt is compiled below.
Matt has a Bachelor of Science degree in Chemistry from the University of Massachusetts. Afterward, Matt received his Ph.D. from Columbia University.
Matt Tremblay is the Vice President of Business Development for The Scripps Research Institute. He also serves as the Chief Operating Officer and Secretary to the Board of Directors, Matt currently runs the day-to-day operation of the institute. He is also responsible for the external relationships with partners. Matt works directly with the CEO on developing the corporate strategy.
Matt simultaneously serves as the CEO of California Institute for Biomedical Research. He was responsible for launching a number of strategic initiatives at Calibr. These include drug discovery collaborations with the Juvenile Diabetes Research Foundation, the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, and Pfizer. Matt has been a part of Calibr's research team since its inception in April 2012. As the leader of the research team, Matt leads a team of biologists "in the discovery of new therapeutic agents for metabolic, cardiovascular, and autoimmune diseases".
We found this article mentioning Matt and his work for Calibr. The article quotes Matt saying: "The partnership with TSRI is critical to our long-term vision for Calibr. We’re thrilled to work alongside TSRI’s world-class faculty and bring Calibr’s capabilities and focus to bear in creating a self-renewing source of new drug discovery opportunities well into the future."
Another article that features Matt and is focused on Scripps talks about Matt helping to launch the startup: "We’re going to essentially run the company without hiring an external team. We’re going to use the employees and capabilities we have built up at Scripps."
Most of media articles mentioning Matt are focused on the recent Scripps launch, and such is this big piece. In the article, they mention that "Tremblay is working with Scripps on translating discoveries into therapies that help patients and businesses that can commercialize drugs." In the article, Matt is quoted saying: "One path forward is getting the attention of world-class investors and folks who are willing to put not just their money but their time [into a startup]."
Matt's work for Calibr was featured on the NVLPartners website where they introduce the collaboration between Intarcia and Calibr. It features a quote from Matt stating: "This collaboration is another example of Calibr’s drive to work with innovative partners who are committed to making a difference in human health. We look forward to working with Intarcia to leverage our peptide technology platform to create transformative new medicines."
Matt's previous work experience includes the role of the Principal Investigator and Vice President of the California Institute for Biomedical Research. Before that he worked as the Research Investigator for GNF. Matt was in charge of a group of scientists in drug discovery for type 1 diabetes.
Matt started as the Graduate Researcher at the Columbia University and the Postdoctoral Fellow at the Scripps Research Institute.
Matt recently received a Life Science Catalyst Award from Biocom, the association that represents the California life science community. The award is meant to celebrate up-and-coming entrepreneurs who are impacting Southern California’s life science industry.
His main interests are drug development, immunology, and chemistry.
Matt Tremblay currently works for Scripps and Calibr, and is known as one of the up-and-coming entrepreneurs in the science industry in California.